NEW YORK (GenomeWeb News) – Goldman Sachs today downgraded Life Technologies and Affymetrix while it upgraded Myriad Genetics and Qiagen.

In a research note, analyst Isaac Ro made revisions to several life science tools and genomics-related firms to favor those "with high exposure to the US and strong [free cash flow] where capital allocation can improve." Changes were made also to reflect rising pressure in the European Union, continuing headwinds to the National Institutes of Health, and slower growth in China.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers describe a way to share data while keeping it secure, Agence France Presse reports.

In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.

India's Council of Scientific and Industrial Research has a new director-general, according to ScienceInsider.

A new study links more than a hundred genes to autism spectrum disorder, Discover's D-brief blog reports.